Clinical effects and security of aripiprazole and risperidone on the treatment of schizophrenia / 中国基层医药

ABSTRACT

Objective To assess the efficacy and safety of aripiprazole and risperidone on the treatment of schizophrenia. Method 80 patients with schizophrenia were randomly divided into risperidone group ( n = 40) and aripiprazole group( n= 40). According to random, controlled principles, all patients were treated for 8 weeks. The positive and negative syndrome scale ( PANSS ), clinical global impression ( CGI ), treatment emergent symptom scale (TESS) and laboratory examinations were used to assess the effectiveness and the safety of the treatment. Results By the end of the 8 weeks treatment,the scores of PANSS in both groups decreased significantly compared to the baseline ( P < 0. 05 ) without statistica differences between groups ( P > 0. 05 ). Total clinical effective rates was 90% in risperidone group and 80% in aripiprazole group, without significant difference between two groups. Digestion adverse reactions in aripiprazole group were significantly more than in risperidone group (P < 0. 05). Conclusion Both aripiprazole and risperidone could treat schizophrenia effectively,and risperidone showed better results.